Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison
- 20 June 2015
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (18) , 2021-2027
Abstract
Purpose: Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk for cognitive impairment; however, evidence is mixed in the existing literature. Our study examined the impact of ADT on impaired cognitive performance and explored potential demographic and genetic predictors of impaired performance.Patients and Methods: Patients with prostate cancer were assessed before or within 21 days of starting ADT (n = 58) and 6 and 12 months later. Age- and education-matched patients with prostate cancer treated with prostatectomy only (n = 84) and men without prostate cancer (n = 88) were assessed at similar intervals. Participants provided baseline blood samples for genotyping. Mean-level cognitive performance was compared using mixed models; cognitive impairment was compared using generalized estimating equations.Results: ADT recipients demonstrated higher rates of impaired cognitive performance over time relative to all controls (P = .01). Groups did not differ at baseline (P > .05); however, ADT recipients were more likely to demonstrate impaired performance within 6 and 12 months (P for both comparisons < .05). Baseline age, cognitive reserve, depressive symptoms, fatigue, and hot flash interference did not moderate the impact of ADT on impaired cognitive performance (P for all comparisons ≥ .09). In exploratory genetic analyses, GNB3 single-nucleotide polymorphism rs1047776 was associated with increased rates of impaired performance over time in the ADT group (P < .001).Conclusion: Men treated with ADT were more likely to demonstrate impaired cognitive performance within 6 months after starting ADT relative to matched controls and to continue to do so within 12 months after starting ADT. If confirmed, findings may have implications for patient education regarding the risks and benefits of ADT.Keywords
This publication has 45 references indexed in Scilit:
- A comparison of cognitive function, sleep and activity levels in disease-free breast cancer patients with or without cancer-related fatigue syndromeBMJ Supportive & Palliative Care, 2012
- Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United StatesUrologic Oncology: Seminars and Original Investigations, 2011
- Acupuncture for Hot Flashes in Patients With Prostate CancerUrology, 2010
- Functional Gene Group Analysis Reveals a Role of Synaptic Heterotrimeric G Proteins in Cognitive AbilityThe American Journal of Human Genetics, 2010
- A meta-analysis of depression severity and cognitive functionJournal of Affective Disorders, 2009
- Meta-analyses of genetic studies on major depressive disorderMolecular Psychiatry, 2007
- Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-upBritish Journal of Cancer, 2006
- The International HapMap ProjectNature, 2003
- Hopkins Verbal Learning Test – Revised: Normative Data and Analysis of Inter-Form and Test-Retest ReliabilityThe Clinical Neuropsychologist, 1998
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987